Chronicles of HBV and the Road to HBV Cure

Author:

Bashir Hamidu Rukaiya1,Hann Richard R.2,Hann Hie-Won1ORCID

Affiliation:

1. Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

2. Liver Disease prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

Abstract

Chronic hepatitis B remains a major public health concern and a leading cause of morbidity and mortality worldwide, specifically through its causative role in chronic liver disease and hepatocellular carcinoma. Worldwide, it affects up to 292 million people. In this paper, we review the historic discovery of the hepatitis B virus and chronicle the significant advances in our understanding of the virus and its interactions with the human host to cause disease. We also overview advancements in therapies for hepatitis B virus and the current absence of curative therapies and highlight on-going therapeutic efforts in search of curative therapies to control transmission and eradicate hepatitis B virus.

Publisher

MDPI AG

Subject

General Medicine

Reference57 articles.

1. Global burden of primary liver cancer in 2020 and predictions to 2040;Rumgay;J. Hepatol.,2022

2. Epidemiology and prevention of hepatitis B virus infection;Hou;Int. J. Med. Sci.,2005

3. Then and now: The progress in hepatitis B treatment over the past 20 years;Hann;World J. Gastroenterol. WJG,2014

4. Hepatitis B (prevention);Norris;BMJ Clin. Evid.,2007

5. HBV cure: Why, how, when?;Levrero;Curr. Opin. Virol.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3